Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Stanford University
University of Pittsburgh
H. Lee Moffitt Cancer Center and Research Institute
University Health Network, Toronto
Northwestern University
Cancer Research UK